Peptide & Supplement Industry Statistics 2026: Market Size, Growth & Trends

The global peptide therapeutics market is valued between roughly $56 billion and $164 billion in 2026, depending on which research firm's report and market definition you're using. The global dietary supplement market is valued between roughly $218 billion and $228 billion in 2026, with somewhat closer agreement between major firms. GLP-1 receptor agonist demand is the most frequently cited driver of peptide market growth. North America is the leading region across the verified peptide therapeutics reports, while Asia-Pacific is frequently identified as a high-growth market.

• Peptide therapeutics: $56.06B–$164.0B, depending on the research firm's market definition.
• Dietary supplements: $218.88B–$228.2B across the two verified reports.
• Peptide growth: Reported CAGRs range from 5.19% to 10.91%.
• Leading peptide region: North America across the three verified reports.
• Major growth theme: GLP-1/metabolic-disorder demand.
• Important caveat: These estimates should not be averaged because their scopes differ.

Three independently verified reports give three different 2026 figures for the global peptide therapeutics market:

Figures are publisher-reported estimates and are not directly comparable because market definitions and methodologies differ.

If you need one number for a headline or a slide, pick the source, name it, and state its year: "Precedence Research estimates the global peptide therapeutics market at $56.06 billion in 2026." That sentence is defensible. "The peptide market is worth $150 billion" — no source, no year — is not. Without a source and defined scope, that figure cannot be evaluated properly.

The three figures above aren't measuring identical things. Grand View Research's report groups revenue by application area including metabolic disorders, cancer, neurological, gastrointestinal, cardiovascular, and pain — and metabolic disorders alone (which includes GLP-1 receptor agonist revenue) accounts for 63.6% of its 2025 total. Precedence Research uses a narrower application breakdown where metabolic disorders is a smaller 22.8% slice of a smaller overall base. Fortune Business Insights segments differently again, by Central Nervous System, respiratory, metabolic, and allergy/immunological categories, with metabolic disorders at 32%.

Put simply: the firms aren't disagreeing about how big peptide drugs are. They're disagreeing about which revenue counts as "peptide therapeutics" in the first place — how much insulin-adjacent and GLP-1 revenue gets folded in, and how metabolic-disorder revenue gets defined and bounded. That's a methodology difference, not a measurement error, and it's worth stating plainly in any content that cites these numbers. The variation reflects differences in market definitions, segmentation, and methodology across the three reports. The reports should therefore be compared as separate estimates rather than treated as measurements of an identical market.

CAGR figures are not comparable across sources unless the base year and forecast horizon match, and here they don't: Grand View Research's 8.7% covers 2026–2033, Precedence Research's 5.19% covers 2026–2035, and Fortune Business Insights' 10.91% covers 2026–2034. A faster CAGR over a shorter window and a slower CAGR over a longer one can land in a similar place — don't average these three percentages together, since they're not describing the same span of years.

All three verified reports identify metabolic disorders and GLP-1-related demand as important factors in the peptide therapeutics market. GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with the metabolic-disorder segment in the market reports reviewed here, although each publisher uses its own segmentation methodology. Grand View Research's report specifically credits "strong commercial performance of GLP-1 receptor agonists" with reinforcing confidence in peptide platforms more broadly and accelerating research investment across the category.

What this means practically: a peptide market forecast that leans heavily on metabolic-disorder or GLP-1 assumptions will diverge more sharply from a forecast that treats those as one segment among several. That's a large part of why the three 2026 estimates above range from $56 billion to $164 billion.

North America is the largest region in all three reports, but the reported share varies enough that it needs its own callout rather than a single number.

Reading the Regional Numbers

• Grand View Research: North America held 61.9% of the peptide therapeutics market in 2025.
• Precedence Research: North America held 45.96% in 2025; Asia-Pacific is projected to grow fastest at a 6.20% CAGR through 2035.
• Fortune Business Insights: North America held 38% in 2025, followed by Europe at 27% and Asia-Pacific at 23%.

A 24-point spread on the same metric, same year, is a direct result of the same scope differences discussed above. The variation reflects differences in market definitions, segmentation, and methodology across the three reports. For brands looking to capture local demand in the most active region, see our analysis on what makes a peptide website rank in Texas.

Two verified reports for the global dietary supplement market:

Figures are publisher-reported estimates and are not directly comparable because market definitions and methodologies differ.

A Source Contradicting Itself

Precedence Research's own dietary supplements report page states in its main body and regional-insights section that "Asia Pacific dominated the market in 2025," giving a specific figure ($78.17 billion). The same page's FAQ section, further down, states "North America region has dominated the global dietary supplements market in 2025." That's an internal inconsistency in the source itself, not something we introduced — worth knowing if you plan to cite this report for regional claims.

The two verified dietary supplement estimates are closer together than the peptide therapeutics estimates, although differences in market definitions and methodology still exist. The two firms land within about $9 billion of each other for the 2026 global estimate.

Grand View Research reports that the United States accounted for 91.4% of North America's dietary supplement revenue in 2025. Combined with North America's 36.1% global share, that puts the US at roughly a third of the global market on this report's figures. Using Grand View Research's reported North American share and US share of North American revenue as a simple calculation produces an implied US market of roughly $75–80 billion for 2026. This is a derived estimate, not a standalone US market figure reported directly by Grand View Research.

The same report cites industry survey data (not Grand View Research's own primary research) indicating that 75–77% of US adults use dietary supplements, with usage higher among older adults — 70–74% of whom report regularly taking supplements, most often for joint, heart, and bone health.

• Vitamins remain the largest ingredient category — 28.2% of global revenue per Grand View Research, with Precedence Research independently confirming vitamins as the leading segment.
• Protein & amino acid supplements are the fastest-growing ingredient category by CAGR (11.9% through 2033 per Grand View Research), driven partly by demand for creatine and collagen.
• Adults remain the largest end-user segment in both verified reports, while the geriatric population shows disproportionately high per-capita usage — Grand View Research estimates geriatric consumers contribute roughly 30% of worldwide sales despite being a smaller population segment.
• Online / direct-to-consumer distribution is the fastest-growing channel in both reports, even though offline retail (pharmacies, health stores) still holds the larger current share.
• Personalized nutrition is repeatedly cited as a growth trend by both firms, tied to advances in health data platforms and, increasingly, AI-driven formulation tools.

A few patterns show up across the verified reports and are worth watching regardless of which market-size figure you land on:

• Oral peptide delivery — reducing reliance on injectables — is repeatedly cited as a growth area, following the commercial success of oral semaglutide.
• Long-acting and depot formulations aimed at reducing dosing frequency continue to expand across peptide therapeutics pipelines.
• Contract development and manufacturing capacity for peptides is expanding materially — Grand View Research's report specifically notes multisite production expansions at major peptide manufacturers.
• Supplement personalization, powered by consumer health data platforms, continues to move from a niche offering toward a mainstream category expectation.

This section is deliberately general — it is not legal advice, and specific regulatory positions should be confirmed with qualified counsel before publication or reliance. A few distinctions are worth keeping straight, because conflating them is the most common error in this category's content, which often requires understanding how we approach RUO peptide website compliance.

• Approved peptide therapeutics are pharmaceutical products that have undergone the applicable regulatory approval process. Research-use-only peptides are marketed for laboratory research and are not approved for human use.
• Dietary supplements are regulated under a different framework (DSHEA) that does not require pre-market FDA approval, though manufacturers are still subject to labeling, safety, and manufacturing rules.
• Research-use-only peptides are marketed for laboratory research rather than human therapeutic use. Their regulatory treatment and labeling requirements can depend on the jurisdiction and product context. They are not included in the three peptide therapeutics market reports reviewed for this article.
• Compounded peptide products (prepared by compounding pharmacies) sit under their own separate regulatory framework, distinct from both approved drugs and RUO products.

None of the three verified market reports used in this article make specific claims about current FDA rulemaking, compounding policy, or RUO enforcement — so this article doesn't either. If your content needs a current regulatory position, that requires its own direct FDA-source check with a publication date attached, not a market-research report.

• Name the source and the year for every figure — "according to Grand View Research (2026)" — rather than presenting a number as an agreed-upon fact.
• When firms disagree by a wide margin, say so and explain the scope difference, instead of averaging or picking whichever number sounds most impressive.
• Never combine a CAGR from one report with a base-year figure from another — the forecast horizons and base years won't line up.
• Keep a visible last-updated date and periodically review the underlying sources, particularly because this article is explicitly positioned as a 2026 statistics resource. (For further strategic content advice, see our guide to Generative Engine Optimization).
• Link the statistic directly to the primary report page where possible, rather than to a secondary blog that cites it.

Every market-size, CAGR, and regional-share figure in this article was independently verified by fetching the original report page from the publishing research firm — not by citing a secondary summary. Two figures from the earlier draft (an RUO-inclusion claim and an averaged regional-share range) were removed because they could not be substantiated against these sources.

• Grand View Research — Peptide Therapeutics Market (2026–2033)
• Precedence Research — Peptide Therapeutics Market Size to 2035
• Fortune Business Insights — Peptide Therapeutics Market, 2026–2034
• Grand View Research — Dietary Supplements Market (2026–2033)
• Precedence Research — Dietary Supplements Market Size to 2035

• Verified 2026 peptide therapeutics estimates range from $56.06B (Precedence Research) to $164.0B (Grand View Research) — the spread comes from differing application scope, not measurement error.
• Verified 2026 dietary supplement estimates are closer together: $218.88B (Precedence Research) to $228.2B (Grand View Research).
• GLP-1 receptor agonist demand is the most consistently cited growth driver across all three verified peptide reports.
• North America's peptide therapeutics share ranges from 38% to 61.9% depending on the source — a direct result of scope differences, not disagreement about underlying demand.
• Precedence Research's own dietary supplements report page contains an internal contradiction about which region led in 2025 — check original sources, even reputable ones, before citing.